2020

12 Patent (10-0118390, Korea)

11 Patent (10-2177781, Korea)
CE Certification of Europe (Palm PCR™ COVID-19 Fast Real-time RT-PCR Kit)
CE Certification of Europe (ACEBiomed COVID-19 IgM/IgG)

10 Merged with HDMedis Co., Ltd.(Mask Business Division)
Seoul MFDS, Manufacture of in-vitro medical devices authorization
(Palm PCR™ Fast COVID-19 Assay)
Apply for a patent (USA, 17061583)
Apply for a patent (China, 202011062211.X)

08 Seoul MFDS, Manufacture of in-vitro medical devices authorization
(ACEBiomed COVID-19 IgM/IgG)
Patent (10-2150821, Korea)

07 Seoul MFDS, Manufacture of in-vitro medical devices authorization
(Palm PCR™ COVID-19 Fast Real-time RT-PCR Kit)

06 NIDS, Manufacture item of in-vitro medical devices authorization
(2020. 5. 1. in-vitro medical devices act enforced)

05 Patent (10-2112456, Korea)
Seoul MFDS, Manufacturing license of in-vitro medical devices authorization
(2020. 5. 1. in-vitro medical devices act enforced)

03 Apply for a patent (China, 202010151845.6)

02 Paper Published (Gut & Liver (2020))

2019

05 Apply for a patent(10-2019-0054100, Korea)

04 MOU with Korea University Guro Hospital IVD Suppot Center

03 Sign an exclusive sales contract(Mousedotcom/Becurator)
of New functional Cosmetics(Diagen Cell)

02 Contract for sole agency of medical product and medicine(The GeneBio)

2017

12 Changed company name (Diagen, Inc.)

11 KOITA, Corporate attached Research Lab Authorization

08 KCL, GMP Certification
NIDS, Medical device manufacture certification
(Replacing authorized → certified)
Gangnam-gu Public Health center, Medical device sales report completed

07 KICOX, Re-registration of production line,

05 Seoul office Relocation (Yeouido → Yeoksam-dong, Gangnam-gu)

02 'Journal of Tropical diseases' submission

01 KIPO, Registration of trademark, service mark
(Cosmegentic cosmetic brand "Iluhwa")

2016

12 Completion ceremony of Research Lab & Production line

11 Busan MFDS, manufacturing medical device authorization
(Re-authorization due to unification of in vitro diagnostic reagent device)

08 Headquarter relocation(Bio 21 center Venture support building)

06 Industry Academy research service Contract with Catholic University
(Purifying raw material for diagnostic device & verification of its effect)

2015

06 Seoul office (Yeouido) opened

05 Inauguration(Management CEO: WangJo Cha, R&D CEO: HyunHyo, Seo)

2012

10 Patent (10-1192295, Korea)

2005

12 KIPO, Patented technology success corporation nomination

08 Ministry of SME, New Technology venture corporation certification

06 KDB, Selected for outstanding company
in technology and value evaluation

05 Neobiodime, Inc. Jinju branch & Daejeon Branch merger

2004

10 Patent (10-0455762, Korea)

2003

02 KITA, Firstly authenticated as Corporate attached Research Lab

2002

12 MFDS, Medical item manufacture permission acquired

11 Manufacture line Registration completed(Daegok-myeon, Jinju-city)

08 MFDS, Medicine supply production licensed

2001

04 Establishment of Neobiodime, Inc.